TheEdgeResearch
Home / Stocks / MRK

Merck & Co., Inc. (MRK)

NYSE Healthcare Drug Manufacturers - General
$148.26 ▼ -0.86%
Market Cap
$366.18B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.21
52-Wk Range
77.58-156.92
CEO
Robert Davis
Country
US
Currency
USD

Merck & Co., Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Rahway, NJ, US. The stock last traded at $148.26, down 0.86% on the session, giving a market capitalisation of $366.18B. On trailing twelve-month figures it carries a trailing P/E of 117.67, a net margin of 4.8%. Its beta of 0.21 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
117.67
Price / Sales
5.51
Price / Book
8.74
EV / EBITDA
29.85
Gross margin
75.4%
Operating margin
16.7%
Net margin
4.8%
Return on equity
Debt / equity
1.29
Current ratio
1.32
Dividend yield
2.3%
Payout ratio
261.5%
Company profile
Exchange
New York Stock Exchange
Employees
74,000
IPO date
1978-01-13
Headquarters
Rahway, NJ, US
About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Comparable companies

Merck & Co., Inc. is most often compared with the following Healthcare names:

ABTAMGNAZNGILDGSKNVONVSPFESNYTMO
More research on MRK
MRK technical analysis MRK TheEdge Score Compare against peers
Open full interactive analysis & DCF →